ADILEarnings•globenewswire•
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Sentiment:Negative (30)
Summary
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire